Cargando…
CD44v8-10 is a marker for malignant traits and a potential driver of bone metastasis in a subpopulation of prostate cancer cells
OBJECTIVE: Bone metastasis is a clinically important outcome of prostate carcinoma (PC). We focused on the phenotypic and functional characterization of a particularly aggressive phenotype within the androgen-independent bone metastasis-derived PC3 cell line. These cells, originated from the spontan...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Compuscript
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330537/ https://www.ncbi.nlm.nih.gov/pubmed/34018387 http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0495 |
_version_ | 1783732740134273024 |
---|---|
author | Fontanella, Rosaria A. Sideri, Silvia Di Stefano, Chiara Catizone, Angiolina Di Agostino, Silvia Angelini, Daniela F. Guerrera, Gisella Battistini, Luca Battafarano, Giulia Del Fattore, Andrea Campese, Antonio Francesco Padula, Fabrizio De Cesaris, Paola Filippini, Antonio Riccioli, Anna |
author_facet | Fontanella, Rosaria A. Sideri, Silvia Di Stefano, Chiara Catizone, Angiolina Di Agostino, Silvia Angelini, Daniela F. Guerrera, Gisella Battistini, Luca Battafarano, Giulia Del Fattore, Andrea Campese, Antonio Francesco Padula, Fabrizio De Cesaris, Paola Filippini, Antonio Riccioli, Anna |
author_sort | Fontanella, Rosaria A. |
collection | PubMed |
description | OBJECTIVE: Bone metastasis is a clinically important outcome of prostate carcinoma (PC). We focused on the phenotypic and functional characterization of a particularly aggressive phenotype within the androgen-independent bone metastasis-derived PC3 cell line. These cells, originated from the spontaneous conversion of a CD44-negative subpopulation, stably express the CD44v8-10 isoform (CD44v8-10(pos)) and display stem cell-like features and a marked invasive phenotype in vitro that is lost upon CD44v8-10 silencing. METHODS: Flow cytometry, enzyme-linked immunoassay, immunofluorescence, and Western blot were used for phenotypic and immunologic characterization. Real-time quantitative polymerase chain reaction and functional assays were used to assess osteomimicry. RESULTS: Analysis of epithelial–mesenchymal transition markers showed that CD44v8-10(pos) PC3 cells surprisingly display epithelial phenotype and can undergo osteomimicry, acquiring bone cell phenotypic and behavioral traits. Use of specific siRNA evidenced the ability of CD44v8-10 variant to confer osteomimetic features, hence the potential to form bone-specific metastasis. Moreover, the ability of tumors to activate immunosuppressive mechanisms which counteract effective immune responses is a sign of the aggressiveness of a tumor. Here we report that CD44v8-10(pos) cells express programmed death ligand 1, a negative regulator of anticancer immunity, and secrete exceptionally high amounts of interleukin-6, favoring osteoclastogenesis and immunosuppression in bone microenvironment. Notably, we identified a novel pathway activated by CD44v8-10, involving tafazzin (TAZ) and likely the Wnt/TAZ axis, known to play a role in upregulating osteomimetic genes. CONCLUSIONS: CD44v8-10 could represent a marker of a more aggressive bone metastatic PC population exerting a driver role in osteomimicry in bone. A novel link between TAZ and CD44v8-10 is also shown. |
format | Online Article Text |
id | pubmed-8330537 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Compuscript |
record_format | MEDLINE/PubMed |
spelling | pubmed-83305372021-08-09 CD44v8-10 is a marker for malignant traits and a potential driver of bone metastasis in a subpopulation of prostate cancer cells Fontanella, Rosaria A. Sideri, Silvia Di Stefano, Chiara Catizone, Angiolina Di Agostino, Silvia Angelini, Daniela F. Guerrera, Gisella Battistini, Luca Battafarano, Giulia Del Fattore, Andrea Campese, Antonio Francesco Padula, Fabrizio De Cesaris, Paola Filippini, Antonio Riccioli, Anna Cancer Biol Med Original Article OBJECTIVE: Bone metastasis is a clinically important outcome of prostate carcinoma (PC). We focused on the phenotypic and functional characterization of a particularly aggressive phenotype within the androgen-independent bone metastasis-derived PC3 cell line. These cells, originated from the spontaneous conversion of a CD44-negative subpopulation, stably express the CD44v8-10 isoform (CD44v8-10(pos)) and display stem cell-like features and a marked invasive phenotype in vitro that is lost upon CD44v8-10 silencing. METHODS: Flow cytometry, enzyme-linked immunoassay, immunofluorescence, and Western blot were used for phenotypic and immunologic characterization. Real-time quantitative polymerase chain reaction and functional assays were used to assess osteomimicry. RESULTS: Analysis of epithelial–mesenchymal transition markers showed that CD44v8-10(pos) PC3 cells surprisingly display epithelial phenotype and can undergo osteomimicry, acquiring bone cell phenotypic and behavioral traits. Use of specific siRNA evidenced the ability of CD44v8-10 variant to confer osteomimetic features, hence the potential to form bone-specific metastasis. Moreover, the ability of tumors to activate immunosuppressive mechanisms which counteract effective immune responses is a sign of the aggressiveness of a tumor. Here we report that CD44v8-10(pos) cells express programmed death ligand 1, a negative regulator of anticancer immunity, and secrete exceptionally high amounts of interleukin-6, favoring osteoclastogenesis and immunosuppression in bone microenvironment. Notably, we identified a novel pathway activated by CD44v8-10, involving tafazzin (TAZ) and likely the Wnt/TAZ axis, known to play a role in upregulating osteomimetic genes. CONCLUSIONS: CD44v8-10 could represent a marker of a more aggressive bone metastatic PC population exerting a driver role in osteomimicry in bone. A novel link between TAZ and CD44v8-10 is also shown. Compuscript 2021-08-15 2021-08-15 /pmc/articles/PMC8330537/ /pubmed/34018387 http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0495 Text en Copyright: © 2021, Cancer Biology & Medicine https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY) 4.0 (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Original Article Fontanella, Rosaria A. Sideri, Silvia Di Stefano, Chiara Catizone, Angiolina Di Agostino, Silvia Angelini, Daniela F. Guerrera, Gisella Battistini, Luca Battafarano, Giulia Del Fattore, Andrea Campese, Antonio Francesco Padula, Fabrizio De Cesaris, Paola Filippini, Antonio Riccioli, Anna CD44v8-10 is a marker for malignant traits and a potential driver of bone metastasis in a subpopulation of prostate cancer cells |
title | CD44v8-10 is a marker for malignant traits and a potential driver of bone metastasis in a subpopulation of prostate cancer cells |
title_full | CD44v8-10 is a marker for malignant traits and a potential driver of bone metastasis in a subpopulation of prostate cancer cells |
title_fullStr | CD44v8-10 is a marker for malignant traits and a potential driver of bone metastasis in a subpopulation of prostate cancer cells |
title_full_unstemmed | CD44v8-10 is a marker for malignant traits and a potential driver of bone metastasis in a subpopulation of prostate cancer cells |
title_short | CD44v8-10 is a marker for malignant traits and a potential driver of bone metastasis in a subpopulation of prostate cancer cells |
title_sort | cd44v8-10 is a marker for malignant traits and a potential driver of bone metastasis in a subpopulation of prostate cancer cells |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330537/ https://www.ncbi.nlm.nih.gov/pubmed/34018387 http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0495 |
work_keys_str_mv | AT fontanellarosariaa cd44v810isamarkerformalignanttraitsandapotentialdriverofbonemetastasisinasubpopulationofprostatecancercells AT siderisilvia cd44v810isamarkerformalignanttraitsandapotentialdriverofbonemetastasisinasubpopulationofprostatecancercells AT distefanochiara cd44v810isamarkerformalignanttraitsandapotentialdriverofbonemetastasisinasubpopulationofprostatecancercells AT catizoneangiolina cd44v810isamarkerformalignanttraitsandapotentialdriverofbonemetastasisinasubpopulationofprostatecancercells AT diagostinosilvia cd44v810isamarkerformalignanttraitsandapotentialdriverofbonemetastasisinasubpopulationofprostatecancercells AT angelinidanielaf cd44v810isamarkerformalignanttraitsandapotentialdriverofbonemetastasisinasubpopulationofprostatecancercells AT guerreragisella cd44v810isamarkerformalignanttraitsandapotentialdriverofbonemetastasisinasubpopulationofprostatecancercells AT battistiniluca cd44v810isamarkerformalignanttraitsandapotentialdriverofbonemetastasisinasubpopulationofprostatecancercells AT battafaranogiulia cd44v810isamarkerformalignanttraitsandapotentialdriverofbonemetastasisinasubpopulationofprostatecancercells AT delfattoreandrea cd44v810isamarkerformalignanttraitsandapotentialdriverofbonemetastasisinasubpopulationofprostatecancercells AT campeseantoniofrancesco cd44v810isamarkerformalignanttraitsandapotentialdriverofbonemetastasisinasubpopulationofprostatecancercells AT padulafabrizio cd44v810isamarkerformalignanttraitsandapotentialdriverofbonemetastasisinasubpopulationofprostatecancercells AT decesarispaola cd44v810isamarkerformalignanttraitsandapotentialdriverofbonemetastasisinasubpopulationofprostatecancercells AT filippiniantonio cd44v810isamarkerformalignanttraitsandapotentialdriverofbonemetastasisinasubpopulationofprostatecancercells AT ricciolianna cd44v810isamarkerformalignanttraitsandapotentialdriverofbonemetastasisinasubpopulationofprostatecancercells |